Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ and 11 more

Show all authors

Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY

Neurology19 Dec 2014Cited by 83 (Europe PMC)

PMID25527270PMCIDPMC4335993DOI10.1212/wnl.0000000000001153PepBankPUB-25527270

Source link PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialSafety outcome
In patients with recurrent or progressive meningioma, pasireotide LAR was well tolerated.
In plain wordsIn patients with recurrent or progressive meningioma, pasireotide LAR was well tolerated.
Peptide
Pasireotide
Outcome
Not applicableTolerability
Study
n = 34
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Treatment was well tolerated.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6).
Summary · context
Patients were stratified by histology (atypical [World Health Organization grade 2] and malignant [grade 3] meningiomas in cohort A and benign [grade 3] in cohort B).
Summary · context
Eighteen patients were accrued in cohort A and 16 in cohort B.
Report a problemFND-2552727009
02HumanNon-randomized trialEfficacy outcome
In recurrent or progressive meningioma cohort A, pasireotide LAR produced no radiographic responses.
In plain wordsIn meningioma cohort A, pasireotide LAR produced no imaging responses.
Peptide
Pasireotide
Outcome
Not applicableRadiographic response, cohort A
Study
n = 18
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Source sentences
Summary
There were no radiographic responses to pasireotide LAR therapy in either cohort.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6).
Summary · context
Patients were stratified by histology (atypical [World Health Organization grade 2] and malignant [grade 3] meningiomas in cohort A and benign [grade 3] in cohort B).
Summary · context
Eighteen patients were accrued in cohort A and 16 in cohort B.
Report a problemFND-2552727001
03HumanNon-randomized trialEfficacy outcome
In meningioma cohort A, 12 patients (67%) achieved stable disease with pasireotide LAR.
In plain wordsIn meningioma cohort A, 67% achieved stable disease with pasireotide LAR.
Peptide
Pasireotide
Outcome
Not applicableStable disease, cohort A
Study
n = 18
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
Patients with stable disease
12 patients
cohort A
Patients with stable disease
67%
cohort A
Source sentences
Summary
Twelve patients (67%) in cohort A and 13 (81%) in cohort B achieved stable disease.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6).
Summary · context
Patients were stratified by histology (atypical [World Health Organization grade 2] and malignant [grade 3] meningiomas in cohort A and benign [grade 3] in cohort B).
Summary · context
Eighteen patients were accrued in cohort A and 16 in cohort B.
Report a problemFND-2552727003
04HumanNon-randomized trialEfficacy outcome
In meningioma cohort A, progression-free survival at 6 months with pasireotide LAR was 17%.
In plain wordsIn meningioma cohort A, 17% remained progression-free at 6 months with pasireotide LAR.
Peptide
Pasireotide
Outcome
Not applicableSix-month progression-free survival, cohort A
Study
n = 18
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
Progression-free survival at 6 months (PFS6)
17%
cohort A
Source sentences
Summary
In cohort A, PFS6 was 17% and median PFS 15 weeks (95% confidence interval: 8-20).
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6).
Summary · context
Patients were stratified by histology (atypical [World Health Organization grade 2] and malignant [grade 3] meningiomas in cohort A and benign [grade 3] in cohort B).
Summary · context
Eighteen patients were accrued in cohort A and 16 in cohort B.
Report a problemFND-2552727005
05HumanNon-randomized trialEfficacy outcome
In meningioma cohort A, median progression-free survival with pasireotide LAR was 15 weeks (95% CI 8-20).
In plain wordsIn meningioma cohort A, median progression-free survival with pasireotide LAR was 15 weeks.
Peptide
Pasireotide
Outcome
Not applicableMedian progression-free survival, cohort A
Study
n = 18
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
Median progression-free survival
15 weeks
cohort A
95% confidence interval
8 to 20 weeks
cohort A, median PFS
Source sentences
Summary
In cohort A, PFS6 was 17% and median PFS 15 weeks (95% confidence interval: 8-20).
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6).
Summary · context
Patients were stratified by histology (atypical [World Health Organization grade 2] and malignant [grade 3] meningiomas in cohort A and benign [grade 3] in cohort B).
Summary · context
Eighteen patients were accrued in cohort A and 16 in cohort B.
Report a problemFND-2552727006
06HumanNon-randomized trialEfficacy outcome
In recurrent or progressive meningioma cohort B, pasireotide LAR produced no radiographic responses.
In plain wordsIn meningioma cohort B, pasireotide LAR produced no imaging responses.
Peptide
Pasireotide
Outcome
Not applicableRadiographic response, cohort B
Study
n = 16
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Source sentences
Summary
There were no radiographic responses to pasireotide LAR therapy in either cohort.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6).
Summary · context
Patients were stratified by histology (atypical [World Health Organization grade 2] and malignant [grade 3] meningiomas in cohort A and benign [grade 3] in cohort B).
Summary · context
Eighteen patients were accrued in cohort A and 16 in cohort B.
Report a problemFND-2552727002
07HumanNon-randomized trialEfficacy outcome
In meningioma cohort B, 13 patients (81%) achieved stable disease with pasireotide LAR.
In plain wordsIn meningioma cohort B, 81% achieved stable disease with pasireotide LAR.
Peptide
Pasireotide
Outcome
Not applicableStable disease, cohort B
Study
n = 16
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
Patients with stable disease
13 patients
cohort B
Patients with stable disease
81%
cohort B
Source sentences
Summary
Twelve patients (67%) in cohort A and 13 (81%) in cohort B achieved stable disease.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6).
Summary · context
Patients were stratified by histology (atypical [World Health Organization grade 2] and malignant [grade 3] meningiomas in cohort A and benign [grade 3] in cohort B).
Summary · context
Eighteen patients were accrued in cohort A and 16 in cohort B.
Report a problemFND-2552727004
08HumanNon-randomized trialEfficacy outcome
In meningioma cohort B, progression-free survival at 6 months with pasireotide LAR was 50%.
In plain wordsIn meningioma cohort B, 50% remained progression-free at 6 months with pasireotide LAR.
Peptide
Pasireotide
Outcome
Not applicableSix-month progression-free survival, cohort B
Study
n = 16
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
Progression-free survival at 6 months (PFS6)
50%
cohort B
Source sentences
Summary
In cohort B, PFS6 was 50% and median PFS 26 weeks (12-43).
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6).
Summary · context
Patients were stratified by histology (atypical [World Health Organization grade 2] and malignant [grade 3] meningiomas in cohort A and benign [grade 3] in cohort B).
Summary · context
Eighteen patients were accrued in cohort A and 16 in cohort B.
Report a problemFND-2552727007
09HumanNon-randomized trialEfficacy outcome
In meningioma cohort B, median progression-free survival with pasireotide LAR was 26 weeks (12-43).
In plain wordsIn meningioma cohort B, median progression-free survival with pasireotide LAR was 26 weeks.
Peptide
Pasireotide
Outcome
Not applicableMedian progression-free survival, cohort B
Study
n = 16
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
Median progression-free survival
26 weeks
cohort B
Interval reported with median PFS
12 to 43 weeks
cohort B, as written (12-43)
Source sentences
Summary
In cohort B, PFS6 was 50% and median PFS 26 weeks (12-43).
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6).
Summary · context
Patients were stratified by histology (atypical [World Health Organization grade 2] and malignant [grade 3] meningiomas in cohort A and benign [grade 3] in cohort B).
Summary · context
Eighteen patients were accrued in cohort A and 16 in cohort B.
Report a problemFND-2552727008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.